A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients with Moderate-to-Severe Atopic Dermatitis.

Study Contact: Madeleine Smee
https://clinicaltrials.gov/ct2/show/NCT04090229

Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (ADVISE)

Study Contact: Madeleine Smee
https://clinicaltrials.gov/ct2/show/NCT05081557

A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat Exposure in the Home

Study Contact: Susi Snitzler 
https://clinicaltrials.gov/ct2/show/NCT04981717

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria (INCEPTION)

Study Contact: Leena Johnson Chacko
https://clinicaltrials.gov/ct2/show/NCT04833855

A randomized, double-blind, placebo-controlled, multi-center, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate to-severe chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment, and who are naïve to omalizumab (RILECSU)

Study Contact: Susi Snitzler
https://clinicaltrials.gov/ct2/show/NCT05107115

A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines (CLOU)

Study Contact: Leena Johnson Chacko
https://clinicaltrials.gov/ct2/show/NCT05032157

A randomized, double-blind, placebo-controlled, multi-center, parallel-group study of dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1-antihistamine treatment (CINDU)

Study Contact: Susi Snitzler
https://clinicaltrials.gov/ct2/show/NCT04681729

A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II) (CHAPTER-1)

Study Contact: Leena Johnson Chacko
https://clinicaltrials.gov/ct2/show/NCT05047185

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of Three Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II (KVD824)

Study Contact: Leena Johnson Chacko
https://clinicaltrials.gov/ct2/show/NCT05055258

Assessing Long-Term Outcomes of DUPIXENT^® Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyposis (AROMA)

Study Contact: Madeleine Smee
https://clinicaltrials.gov/ct2/show/NCT04959448

A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy

Study Contact: Susi Snitzler
https://clinicaltrials.gov/ct2/show/NCT04984876